Kaleido Biosciences Inc (KLDO) Initiated with a Buy at Chardan Capital


Chardan Capital analyst Taylor Feehley initiated coverage with a Buy rating on Kaleido Biosciences Inc (KLDO) today and set a price target of $17.50. The company’s shares closed yesterday at $15.10.

Feehley observed:

“We initiate coverage of Buy rating (PT$17.50) on its differentiated approach to modulate microbiome functionality. Kaleido is developing Microbiome Metabolic Therapies (MMTs), synthetic glycans designed to alter the metabolic profile of the endogenous microbiome. This technology may be applicable in scenarios where blocking specific toxic metabolites could improve health (e.g. the company’s lead programs in hyperammonemia), where providing a competitive advantage to certain commensal strains can restore health (e.g. in infectious disease), or where promoting the production of beneficial metabolites (e.g. short chain fatty acids) may improve pathology.”

According to TipRanks.com, Feehley is a 1-star analyst with an average return of -3.8% and a 60.0% success rate. Feehley covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Evelo Biosciences Inc, and Assembly Biosciences.

Kaleido Biosciences Inc has an analyst consensus of Strong Buy, with a price target consensus of $17.70.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.96 and a one-year low of $12.50. Currently, Kaleido Biosciences Inc has an average volume of 122.8K.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KLDO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kaleido Biosciences, Inc. is a healthcare company, which focuses on leveraging the potential of the microbiome organ to treat disease and improve human health. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan in 2015 and is headquartered in Lexington, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts